Zobrazeno 1 - 10
of 329
pro vyhledávání: '"Anti-Epidermal Growth Factor Receptor"'
Autor:
Yang Wang, Xiangyuan Li, Tongmin Huang, Dongying Wang, Yujing He, Mengfei Wei, Yujie Chen, Matao Zheng, Yetan Shi, Jianjian Zhang
Publikováno v:
World Journal of Surgical Oncology, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Adding anti-epidermal growth factor receptor (anti-EGFR) target agents to conversion therapy may improve the resection rates and survival of patients with potentially resectable metastatic colorectal cancer (mCRC). This study aims
Externí odkaz:
https://doaj.org/article/40957d65644b483c902566ce98fcad4d
Autor:
Lin Yang, Wen Zhang, Nanfeng Fan, Peiguo Cao, Ying Cheng, Lingjun Zhu, Suxia Luo, Hong Zong, Yuxian Bai, Jianfeng Zhou, Yanhong Deng, Yi Ba, Tianshu Liu, Mayinuer Aili, Xianli Yin, Kangsheng Gu, Guanghai Dai, Jieer Ying, Jianhua Shi, Yajie Gao, Wei Li, Guohua Yu, Liangzhi Xie, Wenlin Gai, Yan Wang, Peng Meng, Yuankai Shi
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104966- (2024)
Summary: Background: Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need for novel therapies. Methods: This is an open-label,
Externí odkaz:
https://doaj.org/article/51a30c01a2774b8782efcb9593d768c2
Publikováno v:
Translational Oncology, Vol 39, Iss , Pp 101797- (2024)
Objectives: To investigate the efficacy and safety of nimotuzumab (NTZ) combined with concurrent chemo-radiotherapy (CCRT) in induction chemotherapy (IC) resistant locally advanced nasopharyngeal carcinoma (LANPC). Materials and methods: A single-arm
Externí odkaz:
https://doaj.org/article/575384c736934dd5af224470e51c3ef9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-17 (2021)
Abstract Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT)
Externí odkaz:
https://doaj.org/article/18ac12ff0ced48138a28043392e259f1
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 938-943 (2021)
Recently, v-raf murine sarcoma viral oncogene homologue B (BRAF) fusions have been identified in multiple cancer types using comprehensive genomic profiling (CGP) assays. BRAF fusions are extremely rare, occurring in
Externí odkaz:
https://doaj.org/article/c611b73ca94a4914a660e189f5d4c9a9
Autor:
Li Liang, Mengling Liu, Xun Sun, Yitao Yuan, Ke Peng, Khalid Rashid, Yiyi Yu, Yuehong Cui, Yanjie Chen, Tianshu Liu
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-22 (2021)
Abstract Background The anti-epidermal growth factor receptor (EGFR) antibody introduces adaptable variations to the transcriptome and triggers tumor immune infiltration, resulting in colorectal cancer (CRC) treatment resistance. We intended to ident
Externí odkaz:
https://doaj.org/article/ea17f6f803694a628272e714f57b4495
Autor:
Chen Chen, Yixin Zhou, Xuanye Zhang, Sha Fu, Zuan Lin, Wenfeng Fang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang
Publikováno v:
Cancer Medicine, Vol 9, Iss 5, Pp 1721-1732 (2020)
Abstract Background Platinum‐based chemotherapy is the standard of care as first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM‐NPC); however, the prognosis of patients with RM‐NPC remains poor. The aim of this study
Externí odkaz:
https://doaj.org/article/4036951860cd477ba79ecc7c99085ba6
Autor:
Anita Archwamety, Nattaya Teeyapun, Teerada Siripoon, Naravat Poungvarin, Suebpong Tanasanvimon, Ekaphop Sirachainan, Charuwan Akewanlop, Krittiya Korphaisarn
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCurrent guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are n
Externí odkaz:
https://doaj.org/article/f93b82fc8322451c8cf7e1084cfcd615
Autor:
Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 152-155 (2019)
Mesenchymal–epithelial transition factor (MET) amplification has been suggested either as a de novo or acquired mechanism of resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy. However, even if MET amplification has been widely
Externí odkaz:
https://doaj.org/article/1642474e458b43f6bb34cbd5ae1dd354